SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.99+1.1%3:26 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (7631)12/30/2002 9:54:23 AM
From: Biomaven  Read Replies (1) of 52153
 
<Frova>

Harold -

I don't think the PFE entry will have much impact on Frova. Frova's differentiating factor from all the other triptans is that it has a much longer half-life, and so is a reasonable choice for people whose migraines recur after a standard triptan, as well as for short-term (3-4 day) migraine prophylaxis for women with menstrual migraine.

On the other hand, my impression is that it doesn't work quite as well (or as quickly) for traditional migraines as do the other triptans.

It also seriously lacks sales and marketing muscle.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News